你即將離開本站

並前往https://www.gov.uk/drug-safety-update/lartruvo-olaratumab-withdrawal-of-the-eu-marketing-authorisation-due-to-lack-of-efficacy

Lartruvo (olaratumab): withdrawal of the EU marketing ...

Lartruvo▽ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy. The ANNOUNCE study failed to show clinical ...

確定！ 回上一頁

查詢 「Due to lacking of」的人也找了：

  1. Due to the lack of
    2.